PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)

Key facts

Study ID
NCT01525238
Run by
AstraZeneca
People needed
53
Starts
2012-07-01
Expected to finish
2014-09-01
Last updated by the study team
2017-05-30

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.